Podcast Episodes
Back to Search
Swiss Biotech Day: Basel based BioVersys successfully completed an approximately CHF 80 million IPO in February to advance its work in antimicrobial resistance
Co-Founder & CEO Marc Gitzinger describes the success factors behind the IPO and walks us through the company's two lead programs. Plus, his thoughts…
1 year, 4 months ago
Swiss Biotech Day: Zurich based LimmaTech Biologics is developing vaccines against antimicrobial resistant pathogens
CEO Franz-Werner Haas describes the rationale for developing vaccines for the antimicrobial space, he explains the company's E. coli based platform, …
1 year, 4 months ago
Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers
CEO Marina Udier describes the vaccine's design, what was presented at AACR, and discussions the company has had with U.S. FDA about running a regist…
1 year, 4 months ago
Swiss Biotech Day: Molecular Partners' CEO and Swiss Biotech Association president Patrick Amstutz shares his take on biotech and previews what to expect from his U.S. listed company in 2025
He describes the clinical multi-specific T-cell engager program that will have data this year, and highlights the idea behind a next-generation logic…
1 year, 4 months ago
At a reception on the eve of Swiss Biotech Day, Swiss Biotech Association CEO Michael Altorfer introduces us to the conference and shares his thoughts on the state of biotech and global collaboration
He describes the goals of Swiss Biotech Day, explains how the Swiss biotech sector is funded more by private investment than perhaps other geographie…
1 year, 4 months ago
Biotech investor Thilo Schroeder of Nextech Invest shares his take on biotech and discusses portfolio companies Revolution Medicines, Tubulis, and Circle Pharma
He describes the history of Nextech, including being an early investor in Blueprint Medicines and Peloton, and discusses the importance of investing …
1 year, 4 months ago
VERAXA Biotech, which is part of Switzerland's Xlife Sciences incubator, will be going public in the U.S. via a SPAC in Q4 of this year. The company uses an AND-gating technology for TCEs and ADCs.
Xlife Sciences CEO Oliver Baumann introduces us to the fund, which is publicly traded in Switzerland, while VERAXA CEO Christoph Antz describes the B…
1 year, 4 months ago
Zurich based CUTISS is developing a personalized tissue therapy that enables on-demand production of living skin for surgeries
Co-Founder & CEO Daniela Marino describes why CUTISS believes denovoSKIN is superior to autografting. She describes how they make it, walks us throug…
1 year, 4 months ago
London based Baseimmune shows BiotechTV the new space it moved into in LBIC's Apex Building in Kings Cross where it will use its AI platform to discover and develop new vaccines
Co-founder & CEO Joshua Blight talks about Baseimmune's platform, which was inspired by the work that happened during COVID both in the UK and abroad…
1 year, 4 months ago
Creyon Bio today announced a collaboration to help Lilly use its AI-powered oligo engineering platform and aptamer-based delivery approach to discover and develop therapies in a range of diseases
Recently named CEO Serge Messerlian, who was previously CEO of Teon Therapeutics and President of Janssen Oncology, describes the platform behind thi…
1 year, 4 months ago